| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006336042 |
| P356 | DOI | 10.2165/00019053-200624110-00003 |
| P698 | PubMed publication ID | 17067191 |
| P5875 | ResearchGate publication ID | 6729460 |
| P2093 | author name string | Mark J Sculpher | |
| Karl P Claxton | |||
| P2860 | cites work | Burden of disease--implications for future research | Q31931949 |
| Health economic guidelines--similarities, differences and some implications | Q34436165 | ||
| Value of information literature analysis: a review of applications in health risk management. | Q35779117 | ||
| A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme | Q35833878 | ||
| Evidence synthesis, parameter correlation and probabilistic sensitivity analysis | Q36359124 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| A rational framework for decision making by the National Institute For Clinical Excellence (NICE). | Q40632683 | ||
| Priority setting in medical technology and medical practice assessment | Q44425883 | ||
| The relation between funding by the National Institutes of Health and the burden of disease | Q47714431 | ||
| Expected value of sample information calculations in medical decision modeling. | Q51999189 | ||
| PRIORITIZING INVESTMENTS IN HEALTH TECHNOLOGY ASSESSMENTCan We Assess Potential Value for Money? | Q60687394 | ||
| Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra | Q61856226 | ||
| An economic approach to clinical trial design and research priority-setting | Q72999283 | ||
| The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies | Q73122940 | ||
| Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy | Q77097011 | ||
| Best research for best health: a new national health research strategy | Q79324633 | ||
| P433 | issue | 11 | |
| P921 | main subject | information analysis | Q59162903 |
| P304 | page(s) | 1055-1068 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Using value of information analysis to prioritise health research: some lessons from recent UK experience | |
| P478 | volume | 24 |
| Q38074914 | A systematic and critical review of the evolving methods and applications of value of information in academia and practice. |
| Q44679857 | Addressing adoption and research design decisions simultaneously: the role of value of sample information analysis |
| Q53284749 | Adjusting Estimates of the Expected Value of Information for Implementation: Theoretical Framework and Practical Application. |
| Q36635503 | Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? |
| Q38960831 | Analytic approaches for research priority-setting: issues, challenges and the way forward |
| Q54957626 | Applying Probabilistic Decision Models to Clinical Trial Design. |
| Q79304976 | Better analysis for better decisions: facing up to the challenges |
| Q39401832 | Beyond disease burden: towards solution-oriented population health. |
| Q36635517 | Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process |
| Q30419845 | Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research |
| Q39462453 | Burden of disease, research funding and innovation in the UK: Do new health technologies reflect research inputs and need? |
| Q31084334 | Causal inference from observational data |
| Q37511706 | Challenges of translating genetic tests into clinical and public health practice |
| Q86574733 | Channeling health economics research initiatives to improve decision-making processes in the EU |
| Q30412048 | Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects |
| Q35074556 | Computer disease simulation models: integrating evidence for health policy |
| Q38026781 | Computer modeling informs study design: vaginal estrogen to prevent mesh erosion after different routes of prolapse surgery. |
| Q37163118 | Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling |
| Q33373185 | Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review |
| Q84311441 | Coping with uncertainty on health decisions: assessing new solutions |
| Q92365357 | Cost-Effectiveness of Pain Management Strategies in Advanced Cancer |
| Q38343692 | Cost-effectiveness and value of information analysis of nutritional support for preventing pressure ulcers in high-risk patients: implement now, research later |
| Q33340356 | Cost-effectiveness of palliation of unresectable esophageal cancer |
| Q36213738 | Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation |
| Q39911359 | Coverage with Evidence Development: applications and issues |
| Q38890570 | Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group |
| Q45928290 | Dimensions of design space: a decision-theoretic approach to optimal research design. |
| Q37923478 | Early assessment of medical technologies to inform product development and market access: a review of methods and applications |
| Q26797183 | Economic evaluations of personalized medicine: existing challenges and current developments |
| Q24187893 | Endoscopic retrograde cholangiopancreatography versus intraoperative cholangiography for diagnosis of common bile duct stones |
| Q27311507 | Estimating development cost of an interactive website based cancer screening promotion program |
| Q35611119 | Evaluation of health research: measuring costs and socioeconomic effects |
| Q37939813 | Evidence for the credibility of health economic models for health policy decision-making: a systematic literature review of screening for abdominal aortic aneurysms. |
| Q38647768 | Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer |
| Q39839838 | Historical Lifetimes of Drugs in England: Application to Value of Information and Cost-Effectiveness Analyses |
| Q87002048 | How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis |
| Q35856280 | Incidence and Costs of Clostridium difficile Infections in Canada |
| Q90379320 | Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study |
| Q33723461 | Long term costs and effects of reducing the number of twin pregnancies in IVF by single embryo transfer: the TwinSing study |
| Q89516476 | Mendelian Randomization analysis of the causal effect of adiposity on hospital costs |
| Q38150747 | Methods to elicit probability distributions from experts: a systematic review of reported practice in health technology assessment |
| Q39391038 | Model-based economic evaluation for medical decision making: learn from the past and prepare for the future |
| Q53622322 | New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. |
| Q36635278 | OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis |
| Q36834267 | OFT, VBP: QED? |
| Q59353323 | Optimal Information Collection Policies in a Markov Decision Process Framework |
| Q44871497 | Orphan drugs for rare diseases: is it time to revisit their special market access status? |
| Q36136786 | Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. |
| Q37556659 | Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research |
| Q40049914 | Population-level intervention and information collection in dynamic healthcare policy. |
| Q38043664 | Post-introduction observation of healthcare technologies after coverage: the Spanish proposal. |
| Q36311418 | Prioritization in comparative effectiveness research: the CANCERGEN Experience. |
| Q36635487 | Recent developments in decision-analytic modelling for economic evaluation |
| Q36040765 | Scaphoid Waist Internal Fixation for Fractures Trial (SWIFFT) protocol: a pragmatic multi-centre randomised controlled trial of cast treatment versus surgical fixation for the treatment of bi-cortical, minimally displaced fractures of the scaphoid w |
| Q37272552 | Sequential biases in accumulating evidence |
| Q38175353 | Systematic assessment of decision-analytic models for chronic myeloid leukemia. |
| Q21245519 | Systematic review of methods for evaluating healthcare research economic impact |
| Q40839705 | THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. |
| Q33691735 | The INVEST project: investigating the use of evidence synthesis in the design and analysis of clinical trials |
| Q55217201 | The economic case for precision medicine. |
| Q40096855 | The half-life of truth: what are appropriate time horizons for research decisions? |
| Q35826614 | The need to balance merits and limitations from different disciplines when considering the stepped wedge cluster randomized trial design |
| Q42839844 | The plausible health benefits of nuts: associations, causal conclusions, and informed decisions |
| Q92212721 | The relationship between government research funding and the cancer burden in South Korea: implications for prioritising health research |
| Q39494022 | The role of value-of-information analysis in a health care research priority setting: a theoretical case study. |
| Q39857289 | The value of value of information: best informing research design and prioritization using current methods. |
| Q38421551 | Time to rethink the systematic review catechism? Moving from 'what works' to 'what happens'. |
| Q42377391 | Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed |
| Q47146849 | United Kingdom Frozen Shoulder Trial (UK FROST), multi-centre, randomised, 12 month, parallel group, superiority study to compare the clinical and cost-effectiveness of Early Structured Physiotherapy versus manipulation under anaesthesia versus arth |
| Q36827936 | Use of a decision-analytic model in a health technology assessment: beyond measuring value for money |
| Q51742037 | Using HTA and guideline development as a tool for research priority setting the NICE way: reducing research waste by identifying the right research to fund. |
| Q37103201 | Using health technology assessment to identify research gaps: an unexploited resource for increasing the value of clinical research. |
| Q36420631 | Value based pricing for NHS drugs: an opportunity not to be missed? |
| Q64963591 | Value of Information Analysis Informing Adoption and Research Decisions in a Portfolio of Health Care Interventions. |
| Q38791479 | Value of Information in Asia: Concepts, Current Use, and Future Directions |
| Q43236695 | Value of Information: A Tool to Improve Research Prioritization and Reduce Waste |
| Q90283709 | Value of Information: Sensitivity Analysis and Research Design in Bayesian Evidence Synthesis |
| Q50939811 | Value of Information: We've Got Speed, What More Do We Need? |
| Q58601695 | Value of information analysis of an early intervention for subthreshold panic disorder: Healthcare versus societal perspective |
| Q37808208 | Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors |
| Q37028675 | Value of information: interim analysis of a randomized, controlled trial of goal-directed hemodynamic treatment for aged patients |
| Q36136744 | Value of research analysis: an application to drug development |
| Q59313958 | Value-of-Information Analysis to Reduce Decision Uncertainty Associated with the Choice of Thromboprophylaxis after Total Hip Replacement in the Irish Healthcare Setting |
| Q37600599 | Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics |
Search more.